We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Diabetes and the kidney.
- Authors
Chowdhury, Tahseen A.; Ali, Omer
- Abstract
Diabetes is the most common cause of end-stage kidney disease. Randomised controlled trials have shown a significant benefit of sodium-glucose transporter-2 inhibitors in patients with diabetic kidney disease (DKD), and guidelines now suggest these drugs should be considered in all patients with DKD irrespective of glucose control. Glucagon-like peptide-1 receptor agonists have shown some benefit in reducing progression of albuminuria in DKD and should also be considered early in the therapeutic pathway. Management of diabetes in patients on renal replacement therapy (dialysis or transplantation) is uniquely challenging. This article outlines guidance on management of glucose in these vulnerable groups of patients.
- Subjects
DIABETES complications; CHRONIC kidney failure; SODIUM-glucose cotransporters; THERAPEUTICS; RENAL replacement therapy; GLUCAGON-like peptide-1 agonists; ALBUMINURIA; DISEASE risk factors
- Publication
Clinical Medicine, 2021, Vol 21, Issue 4, pe318
- ISSN
1470-2118
- Publication type
Article
- DOI
10.7861/clinmed.2021-0144